

Czary A Szczylik

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3604370/czary-a-szczylik-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139
papers

23,272
citations

39
h-index

141
g-index

141
ext. papers

26,339
ext. citations

6.4
avg, IF

6.09
L-index

#	Paper	IF	Citations
139	Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. <i>Frontiers in Immunology</i> , 2020 , 11, 613114	8.4	22
138	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019 , 42, 1878-1892	3.5	5
137	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019 , 9, 7754	4.9	3
136	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. <i>Journal of Cell Communication and Signaling</i> , 2019 , 13, 381-394	5.2	15
135	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1116-1127	59.2	1327
134	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019 , 16, 655-673	5.5	12
133	External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 526-532	4.2	16
132	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019 , 71, 149-163	2.2	13
131	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 143-148	7	7
130	Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e685-e693	3.3	46
129	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. <i>Cytotechnology</i> , 2018 , 70, 761-782	2.2	3
128	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2018 , 14, 385-397	6.4	3
127	Role of WNT/ECatenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 257-265	3.3	7
126	Immune consequences of anti-angiogenic therapy in renal cell carcinoma. <i>Wspolczesna Onkologia</i> , 2018 , 22, 14-22	1	6
125	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. <i>Wspolczesna Onkologia</i> , 2018 , 22, 48-55	1	24
124	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018 , 35, 91	3.7	2
123	Involvement of the CB cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. <i>BMC Cancer</i> , 2018 , 18, 583	4.8	26

122	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. <i>International Journal of Oncology</i> , 2018 , 52, 768-786	4.4	3
121	Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors. <i>Anticancer Research</i> , 2018 , 38, 359-365	2.3	10
120	Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. <i>Cancer Research and Treatment</i> , 2018 , 50, 103-110	5.2	24
119	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. <i>Cytotechnology</i> , 2017 , 69, 565-578	2.2	10
118	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 151-162	5.4	4
117	Renin angiotensin system deregulation as renal cancer risk factor. <i>Oncology Letters</i> , 2017 , 14, 5059-5068	2.6	26
116	Functional significance of CD105-positive cells in papillary renal cell carcinoma. <i>BMC Cancer</i> , 2017 , 17, 21	4.8	15
115	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. <i>Future Oncology</i> , 2017 , 13, 593-602	3.6	4
114	Three-dimensional cell culture model utilization in cancer stem cell research. <i>Biological Reviews</i> , 2017 , 92, 1505-1520	13.5	72
113	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017 , 13, 31-49	3.6	15
112	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. <i>Cell and Bioscience</i> , 2017 , 7, 71	9.8	18
111	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017 , 8, 329	5.6	5
110	Axitinib in sequential therapy in metastatic renal cell carcinoma. <i>Wspolczesna Onkologia</i> , 2016 , 20, 418-420		0
109	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F424-36	4.3	17
108	Hormone signaling pathways as treatment targets in renal cell cancer (Review). <i>International Journal of Oncology</i> , 2016 , 48, 2221-35	4.4	21
107	Triiodothyronine regulates cell growth and survival in renal cell cancer. <i>International Journal of Oncology</i> , 2016 , 49, 1666-78	4.4	9
106	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016 , 15, 83	42.1	129
105	Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 295-304	3.5	4

104	Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 1	2.3	13
103	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. <i>Oncology Letters</i> , 2016 , 11, 1101-1104	2.6	8
102	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. <i>PLoS ONE</i> , 2016 , 11, e0165718	3.7	23
101	Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review. <i>Nuclear Medicine Review</i> , 2016 , 19, 54-7	0.3	1
100	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. <i>Current Pharmaceutical Design</i> , 2016 , 22, 1756-66	3.3	29
99	Thyroid Hormones as Renal Cell Cancer Regulators. <i>Journal of Signal Transduction</i> , 2016 , 2016, 1362407		6
98	Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	27
97	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016 , 16, 453	4.8	30
96	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. <i>Oncology Letters</i> , 2016 , 12, 3555-3562	2.6	11
95	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. <i>International Journal of Molecular Medicine</i> , 2016 , 38, 1887-1894	4.4	20
94	Chemotherapy of pancreatic solid pseudopapillary carcinoma – A case report and a literature review. <i>Cancer Treatment Communications</i> , 2016 , 7, 47-51		3
93	Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 457-464	3.3	23
92	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. <i>Oncology Reports</i> , 2016 , 35, 1433-435	3.5	9
91	Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 215-20	2.8	11
90	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016 , 69, 226-235	7.5	45
89	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016 , 65, 102-8	7.5	51
88	Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis. <i>Future Oncology</i> , 2015 , 11, 2831-40	3.6	6
87	Future perspectives for mTOR inhibitors in renal cell cancer treatment. <i>Future Oncology</i> , 2015 , 11, 801-13.6	3.6	12

86	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. <i>Future Oncology</i> , 2015 , 11, 17-26	3.6	13
85	Interleukin-6 as an emerging regulator of renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 476-85	2.8	38
84	Insulin and IGFs in renal cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2015 , 22, R253-64	5.7	42
83	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. <i>Stem Cell Reviews and Reports</i> , 2015 , 11, 919-43	6.4	59
82	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. <i>Future Oncology</i> , 2015 , 11, 2267-82	3.6	22
81	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 283-96	5.6	60
80	Mutation of the gene as a prognostic factor in patients with colorectal cancer. <i>Oncology Letters</i> , 2015 , 10, 1423-1429	2.6	8
79	Impaired glucose metabolism treatment and carcinogenesis. <i>Oncology Letters</i> , 2015 , 10, 589-594	2.6	4
78	The Role of Diabetes in Molecular Pathogenesis of Cancer. <i>Current Signal Transduction Therapy</i> , 2015 , 10, 10-16	0.8	1
77	Biology of renal tumour cancer stem cells applied in medicine. <i>Wspolczesna Onkologia</i> , 2015 , 19, A44-51	1	12
76	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2015 , 6, 178	8.3	52
75	Molecular basis of carcinogenesis in diabetic patients (review). <i>International Journal of Oncology</i> , 2015 , 46, 1435-43	4.4	7
74	Wnt/ β -catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. <i>Journal of Ovarian Research</i> , 2014 , 7, 16	5.5	57
73	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 31-41	11.2	54
72	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 286-96	21.7	215
71	Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). <i>International Journal of Oncology</i> , 2014 , 44, 349-63	4.4	30
70	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 210-218	0.8	18
69	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014 , 8, 218-228	0.8	56

68	Metastasis-Initiating Cells in Renal Cancer. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 240-246	0.8	16
67	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. <i>Future Oncology</i> , 2014 , 10, 2493-508	3.6	7
66	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. <i>Future Oncology</i> , 2014 , 10, 2177-87	3.6	14
65	The use of sunitinib in renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 983-99	3.5	6
64	Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial. <i>Oncologist</i> , 2014 , 19, 356-7	5.7	4
63	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. <i>Oncology Letters</i> , 2014 , 8, 1312-1316	2.6	7
62	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014 , 44, 1736-44	4.4	23
61	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2014 , 10, 1095-111	3.6	27
60	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014 , 4, 194	5.3	18
59	Renal cell carcinoma with intramyocardial metastases. <i>BMC Urology</i> , 2014 , 14, 73	2.2	9
58	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway targeted therapy and one prior mTOR inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 473-473	2.2	1
57	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. <i>Current Signal Transduction Therapy</i> , 2014 , 8, 203-209	0.8	6
56	Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 25	12.8	38
55	Ovarian cancer as a genetic disease. <i>Frontiers in Bioscience - Landmark</i> , 2013 , 18, 543-63	2.8	14
54	A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. <i>European Journal of Cancer</i> , 2013 , 49, 1287-96	7.5	335
53	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3791-9	2.2	310
52	Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib. <i>Journal of Oncology Pharmacy Practice</i> , 2013 , 19, 186-9	1.7	9
51	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. <i>Anti-Cancer Drugs</i> , 2013 , 24, 431-40	2.4	11

50	Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. <i>OncoTargets and Therapy</i> , 2013 , 6, 967-76	4.4	23
49	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 82, 323-37	7	29
48	A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2012 , 124, 205-9	4.9	15
47	Treatment selection in metastatic renal cell carcinoma: expert consensus. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 327-37	19.4	108
46	Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy. <i>Wspolczesna Onkologia</i> , 2012 , 16, 382-7	1	1
45	Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. <i>Wspolczesna Onkologia</i> , 2012 , 16, 250-3	1	1
44	Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors. <i>Wspolczesna Onkologia</i> , 2012 , 16, 90-3	1	
43	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. <i>Nature Medicine</i> , 2012 , 18, 1254-61	50.5	636
42	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. <i>Cancer</i> , 2012 , 118, 6152-61	6.4	89
41	Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 493-7	2.7	6
40	K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1235-43	4.6	8
39	Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 159-74	4	14
38	Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. <i>Kidney and Blood Pressure Research</i> , 2012 , 35, 18-25	3.1	30
37	Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. <i>Kidney and Blood Pressure Research</i> , 2012 , 35, 468-76	3.1	13
36	Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?. <i>Archives of Medical Science</i> , 2012 , 8, 528-32	2.9	6
35	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet, The</i> , 2011 , 378, 1931-9	40	1406
34	M-TOR inhibitors in the treatment of advanced renal cell carcinoma. <i>Wspolczesna Onkologia</i> , 2011 , 6, 343-349	1	
33	Optimal chemotherapy treatment for patients with advanced colorectal cancer. <i>Wspolczesna Onkologia</i> , 2011 , 1, 31-39	1	

32	Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). <i>Oncology Letters</i> , 2011 , 2, 3-11	2.6	6
31	A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. <i>BJU International</i> , 2011 , 107, 1190-9	5.6	17
30	Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. <i>Gynecologic Oncology</i> , 2011 , 123, 33-6	4.9	43
29	The role of Tau protein in resistance to paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 553-7	3.5	47
28	Prognostic significance of Wnt-1, E-catenin and E-cadherin expression in advanced colorectal carcinoma. <i>Pathology and Oncology Research</i> , 2011 , 17, 955-63	2.6	55
27	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011 , 117, 501-9	6.4	110
26	Bevacizumab plus irinotecan in treatment of recurrent brain gliomas. <i>Wspolczesna Onkologia</i> , 2010 , 4, 253-258	1	
25	Efficacy and safety of surgical and chemoimmunotherapy combination treatment in patients with renal carcinoma and pulmonary metastases. <i>Wspolczesna Onkologia</i> , 2010 , 1, 39-43	1	
24	Colorectal cancer in the course of familial adenomatous polyposis syndrome ("de novo" pathogenic mutation of APC gene): case report, review of the literature and genetic commentary. <i>Archives of Medical Science</i> , 2010 , 6, 283-7	2.9	7
23	Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer. <i>International Heart Journal</i> , 2010 , 51, 141-5	1.8	3
22	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. <i>Clinical Cancer Research</i> , 2010 , 16, 5539-47	12.9	161
21	Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. <i>Kidney and Blood Pressure Research</i> , 2010 , 33, 360-7	3.1	21
20	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010 , 36, 16-23	14.4	42
19	Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010 , 46, 2432-40	7.5	62
18	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1061-8	2.2	1944
17	Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. <i>Cancer Investigation</i> , 2010 , 28, 856-64	2.1	30
16	Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 283-92	4.9	2
15	Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 371-8	4.9	24

14	The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010 , 1806, 82-95	11.2	39
13	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3312-8 ²	2.2	897
12	Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , 2009 , 48, 921-5	3.2	6
11	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1280-9	2.2	404
10	Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 61-7	6.4	142
9	Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 815-21	4.9	5
8	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3584-90	2.2	1729
7	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology, The</i> , 2009 , 10, 757-63	21.7	478
6	Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. <i>European Journal of Cancer</i> , 2008 , 44, 2608-14	7.5	81
5	Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1454-63	9.7	110
4	Sorafenib in advanced clear-cell renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 125-34	59.2	4006
3	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. <i>Lancet, The</i> , 2007 , 370, 2103-11	40	1856
2	Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. <i>Journal of Urology</i> , 2007 , 178, 1901-5	2.5	53
1	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2007 , 356, 115-24	59.2	4650